Podcast Summary: Masters in Business – "Targeting IgA Nephropathy"

Podcast: Masters in Business (Bloomberg)
Episode: Targeting IgA Nephropathy (Sponsored Content)
Date: November 9, 2025
Host: Jordan Goss Poirier (Bloomberg Media Studios)
Guests:

• Rachel Benton (Patient)
• Dr. Jonathan Barrett (University of Leicester)
• Mark Bunage (Vertex Pharmaceuticals)
• Dr. Manish Masky (Vertex Pharmaceuticals)

Overview

This episode of "Targeting the Toughest Diseases," produced by Bloomberg Media Studios and sponsored by Vertex Pharmaceuticals, delves into IgA nephropathy (IgAN), a rare and progressive kidney disease. Through the personal story of Rachel Benton, insights from leading nephrologists, and a look at innovative biotech research, the episode explores both the human and scientific challenges of diagnosing, living with, and ultimately seeking treatments for IgA nephropathy.

Key Discussion Points & Insights

1. Rachel’s Story: The Human Face of IgA Nephropathy

• Diagnosis by Accident:

  • Rachel Benton discovers she has IgA nephropathy after a routine urine test during her pregnancy reveals protein in her urine.
  • “We know it is IgA nephropathy. It's a rare kidney disease. There is not a cure. We don't have a cause.” (Rachel Benton, 01:34)
  • Rachel describes the shock, uncertainty, and distress following her diagnosis and the long-term impact on her daily life and family.

• Daily Life with IgAN:

  • Rachel manages her condition with diet changes and medication for blood pressure and cholesterol.
  • Experiences severe, chronic fatigue: “It's not just new mom tiredness, but debilitating fatigue, where she'll sleep for 12 hours and still need a midday nap.” (Narration, 05:51)
  • Emotional toll: Guilt about potential future health and being present for her son and husband.

2. Medical Insight: Understanding IgA Nephropathy

• What is IgA Nephropathy?

  • Dr. Jonathan Barrett explains:

    • IgA nephropathy is an underdiagnosed and historically under-researched chronic kidney disease.
    • The disease’s early symptoms are subtle and often picked up incidentally, typically by a routine urine test.
    • “Normally, the patients I see have no idea why they're coming to see a kidney doctor.” (Dr. Jonathan Barrett, 08:11)
    • IgA protein, meant to defend the body, accumulates in the kidneys, clogging filters and leading to inflammation, scarring, and kidney failure.

  • Genetic and Biological Complexity:

    • There’s suspected but unconfirmed genetic involvement.
    • Only definitive diagnosis: kidney biopsy.
    • The majority of adults with IgAN will progress to end-stage renal disease within 20 years of diagnosis, requiring dialysis or transplant.

  • Mental and Emotional Burden:

    • Unpredictability of disease progression causes constant anxiety:

      “The big challenge is actually the impact on mental wellness... That sense of uncertainty can be absolutely devastating for young people." (Dr. Barrett, 10:45)

3. Vertex Pharmaceuticals: Innovating for IgAN Treatment

• Vertex’s Approach:

  • Mark Bunage (Vertex):
    • Focus on serious diseases with significant unmet needs, leveraging scientific innovation.
    • “We focus on causal human biology and on human validated targets… we are completely modality agnostic. We'll use whatever is the right tool in the toolbox… to come up with a transformative therapy.” (Mark Bunage, 12:16)

• Scientific Advances:

  • Dr. Manish Masky (Vertex):
    • Loss of control in B cells triggers IgAN.
    • Proteins BAF and APRIL are key drivers in B cell misregulation.
    • “BAF and APRIL really seem to be two of the most critical proteins driving this transition from something that would protect us to something that would actually make antibodies that will harm our native tissues.” (Dr. Masky, 14:12)
    • Vertex aims to develop therapies targeting both BAF and APRIL to restore immune balance, potentially halting disease progression.

4. Advocacy and Advice

• Rachel advocates for regular urine testing as a simple measure for early detection:

  • “All of my friends, because of this, I'm like, please get your yearlies done, but also ask for that urine test…” (Rachel Benton, 17:25)

• General advice: Kidney health should be a routine conversation with healthcare providers.

Notable Quotes & Memorable Moments

• Rachel on receiving her diagnosis:

  “I got off the phone and just cried. I think for probably two days straight.” (05:21)

• Dr. Barrett on the uncertainty of the disease:

  “Some patients do really well with IGA nephropathy and others end up on dialysis relatively quickly. And that's the bit we haven't quite worked out yet.” (09:10)

• Dr. Masky on scientific approach:

  “There's a need to cast the widest net to catch the main actors involved in in the pathogenesis of IgA nephropathy. What we hope to see with this approach is the potential to restore immune balance for our patients…” (15:27)

• Rachel on living with the uncertainty:

  “Some days I can be like, you know what? I am a lawyer. I got this. Everything's great. And other days it's like I am not okay. And I feel like I could just crawl under a rock and stay there.” (16:23)

Important Timestamps

• 01:11-01:46 – Rachel’s diagnosis and reaction
• 04:25-05:21 – Rachel’s uncertainty and emotional impact post-diagnosis
• 07:35-08:36 – Dr. Barrett: Symptoms, underdiagnosis, and initial presentation
• 09:45-10:39 – Dr. Barrett: Pathophysiology – how IgA harms kidneys
• 10:45-11:25 – Dr. Barrett: Psychological and life impact
• 12:07-12:38 – Mark Bunage: Vertex’s research philosophy
• 13:24-15:21 – Dr. Masky: B cell dysfunction, BAF and APRIL’s roles
• 16:23-17:25 – Rachel: Living with uncertainty, mental health, and advice for others

Conclusion

This episode effectively brings together the poignant story of a young mother impacted by a rare disease and the innovators in medicine working to change patient outcomes. IgA nephropathy, once “invisible” in medical research, is gaining new attention thanks to advances in understanding immune system dysfunction and companies like Vertex Pharmaceuticals pursuing transformative, targeted treatments. The episode closes with a call for awareness: early testing and proactive kidney health discussions can be life-changing.